Global Rheumatic Heart Disease Market Research and Forecast 2018-2023
Rheumatic heart disease is an inflammatory disease that start with a normal strep throat, fever and multiple joint pains. Further, non-treating of these symptoms involve heart and damages the heart valves and leads to rheumatic heart disease(RHD). Streptococcus pyogenes are the main bacterium which causes rheumatic fever. These infectious agents came in contact with human body via various toxic materials from environment such as water, food, air, toxic gases, smoke, and pollution. Increasing environmental pollution resulting in higher prevalence of viral and fungal infection is one of the major factor motivating the growth of this market. In addition, increasing healthcare expenditure by government to tackle rising prevalence of cardiovascular disease is another motivating factor for the market. However, its high medical treatment and limited healthcare facilities in emerging economies may restrict the growth of this market. Furthermore, Continuous improvement by leading market players in Rheumatic heart disease drug and development in biotechnology has brought new opportunity to this market.
Geographically Rheumatic heart disease market is divided into north America, Europe, Asia pacific and rest of the world. The growing number of collaboration and partnership by major pharmaceutical companies, to provide better healthcare facilities in Europe is the market driver in the European region. The global players in the rheumatic heart disease market includes Abbott laboratories, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer. The strategy adopted in these companies are continuous investments in R&D which made them progress over the past several years in various drug discovery for Rheumatic heart diseases. Continuous improvement on Rheumatic heart disease drug enable market player to offer high-value product and services at lower cost.
RESEARCH METHODOLOGY
The market study of global Rheumatic heart disease market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
financial reports of companies involved in the market
authentic public databases such as the FDA, who and others
whitepapers, research-papers and news blogs
company websites and their product catalogue.
The report is intended for Rheumatic heart disease drug manufacturers, diagnostic centers, investing companies, government organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating in delivering insights into the market for better business decisions.
THE REPORT COVERS:
Comprehensive research methodology of global Rheumatic heart disease market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Rheumatic heart disease market.
Insights about market determinants which are stimulating the global Rheumatic heart disease market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Geographically Rheumatic heart disease market is divided into north America, Europe, Asia pacific and rest of the world. The growing number of collaboration and partnership by major pharmaceutical companies, to provide better healthcare facilities in Europe is the market driver in the European region. The global players in the rheumatic heart disease market includes Abbott laboratories, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer. The strategy adopted in these companies are continuous investments in R&D which made them progress over the past several years in various drug discovery for Rheumatic heart diseases. Continuous improvement on Rheumatic heart disease drug enable market player to offer high-value product and services at lower cost.
RESEARCH METHODOLOGY
The market study of global Rheumatic heart disease market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analysing various regional players, regional tax laws and policies, consumer behaviour and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
financial reports of companies involved in the market
authentic public databases such as the FDA, who and others
whitepapers, research-papers and news blogs
company websites and their product catalogue.
The report is intended for Rheumatic heart disease drug manufacturers, diagnostic centers, investing companies, government organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating in delivering insights into the market for better business decisions.
THE REPORT COVERS:
Comprehensive research methodology of global Rheumatic heart disease market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Rheumatic heart disease market.
Insights about market determinants which are stimulating the global Rheumatic heart disease market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1. REPORT SUM MARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOM MENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING ENVIROMENTAL POLLUTION
3.1.2. INCREASE IN HEALTHCARE EXPENDITURE BY GOVERNMENT IN EMERGING NATION
3.1.3. RISING PREVALANCE OF VIRAL AND FUNGAL INFECTION
3.1.4. RISING INCIDENCES OF CARDIOVASCULAR DISEASE
3.2. RESTRAINT
3.2.1. HIGH COST OF SURGICAL PROCEDURE AND MEDICATION
3.2.2. INADEQUATE HEALTH FACILITIES IN DEVELOPING NATIONS
3.3. OPPORTUNITY
3.3.1. TECHNOLOGICAL ADVANCEMENT AND DEVELOPMENT IN BIOTECHNOLOGY
3.3.2. INCREASE IN R&D SPENDING BY GOVERNMENT AND MARKET PLAYER IN DURG DEVELOPMENT
4. MARKET SEGMENTATION
4.1. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY TREATMENT
4.1.1. ANITIBIOTICS MEDICATION
4.1.2. ANTI-CONVULSANT MEDICATION
4.1.3. ANTI-INFLAMATORY TREATMENT
4.1.4. SURGICAL TREATMENT
4.2. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY END-USER
4.2.1. HOSPITAL
4.2.2. DIAGNOSTIC CENTRE
4.2.3. RESEARCH CENTRE
4.2.4. OTHERS
4.3. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY TYPE
4.3.1. VALVE
4.3.1.1. AORTIC VALVE
4.3.1.2. MITRAL VALVE
4.3.2. MYOCARDITIS
4.3.3. PERICARDITIS
4.4. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY DIAGNOSTIC TEST
4.4.1. ELECTROCARDIOGRAM
4.4.2. ECHOCARDIOGRAM
4.4.3. BLOOD TEST
4.4.4. Imaging
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. BAYER AG
7.3. BIOTRONIK
7.4. BOSTON SCIENTIFIC CORPORATION
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.6. C. R. BARD, INC.
7.7. CARDINAL HEALTH
7.8. COOK MEDICAL
7.9. F. HOFFMANN-LA ROCHE LTD
7.10. GE HEALTHCARE
7.11. INTERVALVE MEDICAL INC.
7.12. NOVARTIS AG
7.13. ON-X LIFE TECHNOLOGIES INC.
7.14. OSYPKA MEDICAL, INC.
7.15. OTSUKA HOLDINGS CO. LTD.
7.16. PERKINELMER, INC.
7.17. PFIZER INC.
7.18. RECKITT BENCKISER GROUP PLC.
7.19. SEIMENS HEALTHINEER
7.20. TORAY INDUSTRIES, INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOM MENDATION
2.2.3. CONCLUSION
2.3. REGULATION
2.3.1.1. UNITED STATES
2.3.1.2. EUROPEAN UNION
2.3.1.3. CHINA
2.3.1.4. INDIA
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. INCREASING ENVIROMENTAL POLLUTION
3.1.2. INCREASE IN HEALTHCARE EXPENDITURE BY GOVERNMENT IN EMERGING NATION
3.1.3. RISING PREVALANCE OF VIRAL AND FUNGAL INFECTION
3.1.4. RISING INCIDENCES OF CARDIOVASCULAR DISEASE
3.2. RESTRAINT
3.2.1. HIGH COST OF SURGICAL PROCEDURE AND MEDICATION
3.2.2. INADEQUATE HEALTH FACILITIES IN DEVELOPING NATIONS
3.3. OPPORTUNITY
3.3.1. TECHNOLOGICAL ADVANCEMENT AND DEVELOPMENT IN BIOTECHNOLOGY
3.3.2. INCREASE IN R&D SPENDING BY GOVERNMENT AND MARKET PLAYER IN DURG DEVELOPMENT
4. MARKET SEGMENTATION
4.1. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY TREATMENT
4.1.1. ANITIBIOTICS MEDICATION
4.1.2. ANTI-CONVULSANT MEDICATION
4.1.3. ANTI-INFLAMATORY TREATMENT
4.1.4. SURGICAL TREATMENT
4.2. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY END-USER
4.2.1. HOSPITAL
4.2.2. DIAGNOSTIC CENTRE
4.2.3. RESEARCH CENTRE
4.2.4. OTHERS
4.3. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY TYPE
4.3.1. VALVE
4.3.1.1. AORTIC VALVE
4.3.1.2. MITRAL VALVE
4.3.2. MYOCARDITIS
4.3.3. PERICARDITIS
4.4. GLOBAL RHEUMATIC HEART DISEASE MARKET, BY DIAGNOSTIC TEST
4.4.1. ELECTROCARDIOGRAM
4.4.2. ECHOCARDIOGRAM
4.4.3. BLOOD TEST
4.4.4. Imaging
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. UK
6.2.2. GERMANY
6.2.3. SPAIN
6.2.4. FRANCE
6.2.5. ITALY
6.2.6. REST OF EUROPE
6.3. APAC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. REST OF APAC
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. ABBOTT LABORATORIES
7.2. BAYER AG
7.3. BIOTRONIK
7.4. BOSTON SCIENTIFIC CORPORATION
7.5. BRISTOL-MYERS SQUIBB COMPANY
7.6. C. R. BARD, INC.
7.7. CARDINAL HEALTH
7.8. COOK MEDICAL
7.9. F. HOFFMANN-LA ROCHE LTD
7.10. GE HEALTHCARE
7.11. INTERVALVE MEDICAL INC.
7.12. NOVARTIS AG
7.13. ON-X LIFE TECHNOLOGIES INC.
7.14. OSYPKA MEDICAL, INC.
7.15. OTSUKA HOLDINGS CO. LTD.
7.16. PERKINELMER, INC.
7.17. PFIZER INC.
7.18. RECKITT BENCKISER GROUP PLC.
7.19. SEIMENS HEALTHINEER
7.20. TORAY INDUSTRIES, INC.
LIST OF TABLES
TABLE 1 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 2 GLOBAL ANITIBIOTICS MEDICATION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 3 GLOBAL ANTI-CONVULSANT MEDICATION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 4 GLOBAL ANTI-INFLAMATORY TREATMENT MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 5 GLOBAL SURGICAL TREATMENT MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 6 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 7 GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 8 GLOBAL DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 9 GLOBAL RESEARCH CENTRE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 10 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 11 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 12 GLOBAL VALVE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 13 GLOBAL MYOCARDITIS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 14 GLOBAL PERICARDITIS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 15 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 16 GLOBAL ELECTROCARDIOGRAM MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 17 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 18 GLOBAL BLOOD TEST MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 19 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 20 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION)
TABLE 21 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 22 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 23 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 24 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 25 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 26 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 27 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 28 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 29 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 30 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 31 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 32 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 33 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 34 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 35 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION)
TABLE 36 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION)
TABLE 37 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION)
TABLE 38 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION)
TABLE 1 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 2 GLOBAL ANITIBIOTICS MEDICATION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 3 GLOBAL ANTI-CONVULSANT MEDICATION MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 4 GLOBAL ANTI-INFLAMATORY TREATMENT MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 5 GLOBAL SURGICAL TREATMENT MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 6 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 7 GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 8 GLOBAL DIAGNOSTIC CENTRE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 9 GLOBAL RESEARCH CENTRE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 10 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 11 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 12 GLOBAL VALVE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 13 GLOBAL MYOCARDITIS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 14 GLOBAL PERICARDITIS MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION).
TABLE 15 GLOBAL RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 16 GLOBAL ELECTROCARDIOGRAM MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 17 GLOBAL ECHOCARDIOGRAM MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 18 GLOBAL BLOOD TEST MARKET RESEARCH AND ANALYSIS, 2017-2023($ MILLION).
TABLE 19 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 20 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION)
TABLE 21 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 22 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 23 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 24 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 25 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 26 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 27 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 28 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 29 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION).
TABLE 30 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION).
TABLE 31 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION).
TABLE 32 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION).
TABLE 33 ASIA PACIFIC RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION).
TABLE 34 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY GEOGRAPHY 2017-2023($ MILLION)
TABLE 35 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TREATMENT 2017-2023($ MILLION)
TABLE 36 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY END-USER 2017-2023($ MILLION)
TABLE 37 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY TYPE 2017-2023($ MILLION)
TABLE 38 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY TREATMENT 2017 VS 2023(IN %)
FIGURE 2 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY END-USER 2017 VS 2023(IN %)
FIGURE 3 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE, BY TYPE 2017 VS 2023(IN %)
FIGURE 4 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION)
FIGURE 5 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 6 UNITED STATES RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 7 CANADA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 8 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 UK RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 GERMANY RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 SPAIN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 FRANCE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 ITALY RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 REST OF EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 ASIA PASIFIC REGION RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 INDIA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 CHINA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 JAPAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF ASIA PACIFIC REGION RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 20 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. BAYER AG
3. BIOTRONIK
4. BOSTON SCIENTIFIC CORPORATION
5. BRISTOL-MYERS SQUIBB COMPANY
6. C. R. BARD, INC.
7. CARDINAL HEALTH
8. COOK MEDICAL
9. F. HOFFMANN-LA ROCHE LTD
10. GE HEALTHCARE
11. INTERVALVE MEDICAL INC.
12. NOVARTIS AG
13. ON-X LIFE TECHNOLOGIES INC.
14. OSYPKA MEDICAL, INC.
15. OTSUKA HOLDINGS CO. LTD.
16. PERKINELMER, INC.
17. PFIZER INC.
18. RECKITT BENCKISER GROUP PLC.
19. SEIMENS HEALTHINEER
20. TORAY INDUSTRIES, INC.
FIGURE 1 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY TREATMENT 2017 VS 2023(IN %)
FIGURE 2 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE BY END-USER 2017 VS 2023(IN %)
FIGURE 3 GLOBAL RHEUMATIC HEART DISEASE MARKET SHARE, BY TYPE 2017 VS 2023(IN %)
FIGURE 4 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, BY DIAGNOSTIC TEST 2017-2023($ MILLION)
FIGURE 5 NORTH AMERICA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 6 UNITED STATES RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 7 CANADA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS 2017-2023($ MILLION)
FIGURE 8 EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 9 UK RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 10 GERMANY RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 11 SPAIN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 12 FRANCE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 13 ITALY RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 14 REST OF EUROPE RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 15 ASIA PASIFIC REGION RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 16 INDIA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 17 CHINA RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 18 JAPAN RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 19 REST OF ASIA PACIFIC REGION RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
FIGURE 20 REST OF THE WORLD RHEUMATIC HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABBOTT LABORATORIES
2. BAYER AG
3. BIOTRONIK
4. BOSTON SCIENTIFIC CORPORATION
5. BRISTOL-MYERS SQUIBB COMPANY
6. C. R. BARD, INC.
7. CARDINAL HEALTH
8. COOK MEDICAL
9. F. HOFFMANN-LA ROCHE LTD
10. GE HEALTHCARE
11. INTERVALVE MEDICAL INC.
12. NOVARTIS AG
13. ON-X LIFE TECHNOLOGIES INC.
14. OSYPKA MEDICAL, INC.
15. OTSUKA HOLDINGS CO. LTD.
16. PERKINELMER, INC.
17. PFIZER INC.
18. RECKITT BENCKISER GROUP PLC.
19. SEIMENS HEALTHINEER
20. TORAY INDUSTRIES, INC.
